Wynnewood, PA (PRWEB) March 10, 2010
Adoodle, Inc, (OTC Pink Sheets: ADDE) announced today that NOXO Stress Relief balm is now available at a price of $ 11.95 for 20 doses. Dr. Warren Chaney, Advisory Board Member said "the new NOXO Stress Relief Balm and Olfactory Nasal Inhaler is effective in relaxing brain waves and reducing stress and toxins while enabling the body's natural balance". Stress causes the entire body to malfunction, creating imbalances in all the systems of the body, resulting in obesity, exhaustion, digestive disorders, circulatory disorders and depression.
The new NOXO Stress Release balm, when applied topically, under the nostrils helps deliver scent molecules into the nose to the olfactory bulb, where the chemical and neurotransmitter messengers are dispensed into the limbic system of the brain. From there, they are forwarded to areas of the central nervous system that mediate emotional, hormonal, metabolic, and stress responses throughout the body. This product is extremely effective in reducing stress and installing calm. Stress is the term used to describe any reaction to a physical, mental or emotional stimulus that upsets the body's natural balance.
Here is one of the best stress relief products to reduce long-term stress, which is known to suppress the immune system. Part of cancer prevention is supporting a healthy immune system so it can do the job of stopping cancer before it has a chance to develop into disease. Whether stress is related to work or family life, most of us experience too much stress in our daily life.
NOXO Anti-Stress balm, a proprietary product formulation of 16 unique molecular ingredients, which are soy-based, is absorbed into the skin and is not visible after application. Based on olfactory perception altering technology, the NOXO line of products is focused on modifying behavior, via the olfactory senses and the limbic system.
Adoodle’s NOXO division is focused on developing a variety of products that can modify behaviors such as appetite, stress, anxiety, mood, memory and sugar cravings. The company's first of eleven products to reach commercialization was NOXO’s Odor inhibitor, which has the ability to alter the brain’s ability to smell horrific odors. The odor is still there and it's not masked. The brain does not however, register its normal reaction to it. The uniquely formulated NOXO Odor Inhibitor is based on the advanced olfactory perception altering technology of all these new NOXO products.
For dealers and inquiries, please consider NOXO’s products to feature as part of your retail store, catalogue or service. Our headquarters are located in Pennsylvania where a seasoned team of business professionals develop winning strategies for products in the health and wellness industry. We are the exclusive manufacturer and/or wholesale distributor for these unique and effective products for modifying behavior. If you have questions or need additional information, please do not hesitate to call (484) 278-1626 or complete our online inquiry form at: http://www.noxoinfo.com/contact.html.
Investor & Media Relations:
Safe Harbor for Public Companies
Statements contained in this release that are not strictly historical are "forward-looking statements." Such forward-looking statements are sometimes identified by words such as "intends," "anticipates," "believes," "expects," and "hopes." The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include, but are not limited to, demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders. Adoodle, "The Company" currently does not file periodic filings with the Securities and Exchange Commission but will publish financials on the Adoodle website as they become available.
333 E. Lancaster Ave.
Wynnewood, PA 19096